Avaí Bio is an emerging biotechnology company partnering with leading-edge biotech firms, universities, scientists, and clinicians to uncover innovative solutions for diverse healthcare challenges, driving the development of advanced therapies that improve patient outcomes and quality of life. Our mission is to transform healthcare through cutting-edge cellular technology and protective live-cell encapsulation, reshaping how patients see their available treatment options.
Avaí Bio currently has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an α-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. Avaí has secured Joint Venture and Licensing Agreements to develop both cell lines.
